These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 18469443)
1. Response to a third-line mitomycin C (MMC)-based chemotherapy in a patient with metastatic pancreatic adenocarcinoma carrying germline BRCA2 mutation. Chalasani P; Kurtin S; Dragovich T JOP; 2008 May; 9(3):305-8. PubMed ID: 18469443 [TBL] [Abstract][Full Text] [Related]
2. Further evidence for prolongation of survival of pancreatic cancer patients by efficacy orientated sequential polychemotherapy (EOSPC) based on serial tumor marker determinations (CA 19-9/CEA). Klapdor R; Bahlo M; Babinsky A Anticancer Res; 2005; 25(3A):1687-91. PubMed ID: 16033083 [TBL] [Abstract][Full Text] [Related]
3. [A case of pancreatic cancer surviving for 7 years 11 months following intra-arterial and portal infusion chemotherapy]. Kenmotsu M; Endo T; Ishii H; Ichikawa J; Tsunemitsu K Gan To Kagaku Ryoho; 1995 Nov; 22(13):1983-5. PubMed ID: 7487131 [TBL] [Abstract][Full Text] [Related]
4. Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature. James E; Waldron-Lynch MG; Saif MW Anticancer Drugs; 2009 Aug; 20(7):634-8. PubMed ID: 19433978 [TBL] [Abstract][Full Text] [Related]
5. Reflections on treatment strategies for palliative chemotherapy of pancreatic cancer. Klapdor R; Bahlo M; Babinsky A; Brenzinger ML Anticancer Res; 2007; 27(4A):1789-94. PubMed ID: 17649774 [TBL] [Abstract][Full Text] [Related]
6. BRCA2 mutations as a universal risk factor for pancreatic cancer has a limited role in Korean ethnic group. Cho JH; Bang S; Park SW; Chung JB; Song SY Pancreas; 2008 May; 36(4):337-40. PubMed ID: 18437078 [TBL] [Abstract][Full Text] [Related]
7. Complete Response to Chemotherapy in Metastatic Pancreatic Carcinoma Associated with Double Heterozygous Germline Mutation in BRCA2 and CHEK2 Genes - a Case Report. Pazderová N; Urbán V; Makovník M; Macák D; Janega P; Chovanec M; Rejleková K; Mardiak J; Mego M Klin Onkol; 2020; 33(3):220-225. PubMed ID: 32683879 [TBL] [Abstract][Full Text] [Related]
8. A carrier of both MEN1 and BRCA2 mutations: case report and review of the literature. Ghataorhe P; Kurian AW; Pickart A; Trapane P; Norton JA; Kingham K; Ford JM Cancer Genet Cytogenet; 2007 Dec; 179(2):89-92. PubMed ID: 18036394 [TBL] [Abstract][Full Text] [Related]
9. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. Tan DS; Rothermundt C; Thomas K; Bancroft E; Eeles R; Shanley S; Ardern-Jones A; Norman A; Kaye SB; Gore ME J Clin Oncol; 2008 Dec; 26(34):5530-6. PubMed ID: 18955455 [TBL] [Abstract][Full Text] [Related]
10. Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy. Sonnenblick A; Kadouri L; Appelbaum L; Peretz T; Sagi M; Goldberg Y; Hubert A Cancer Biol Ther; 2011 Aug; 12(3):165-8. PubMed ID: 21613821 [TBL] [Abstract][Full Text] [Related]
11. Possible use of combination chemotherapy with mitomycin C and methotrexate for metastatic breast cancer pretreated with anthracycline and taxanes. Tanabe M; Ito Y; Tokudome N; Sugihara T; Miura H; Takahashi S; Seto Y; Iwase T; Hatake K Breast Cancer; 2009; 16(4):301-6. PubMed ID: 19205831 [TBL] [Abstract][Full Text] [Related]
12. Oxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advanced pancreatic cancer. Novarino A; Satolli MA; Chiappino I; Giacobino A; Bellone G; Rahimi F; Milanesi E; Bertetto O; Ciuffreda L Am J Clin Oncol; 2009 Feb; 32(1):44-8. PubMed ID: 19194124 [TBL] [Abstract][Full Text] [Related]
13. [Isolated hypoxic perfusion with mitomycin C confers no benefit for patients with advanced pancreatic carcinoma]. Petrowsky H; Heinrich S; Staib-Sebler E; Gog C; Janshon G; Lorenz M Langenbecks Arch Chir Suppl Kongressbd; 1998; 115():1351-3. PubMed ID: 9931879 [TBL] [Abstract][Full Text] [Related]
14. A 67-year-old woman with BRCA 1 mutation associated with pancreatic adenocarcinoma. Lowery M; Shah MA; Smyth E; Epstein A; Segal A; Rosengarten O; Isacson R; Drukker L; Keinan A; Rachkiman M; Reissman P; Gabizon A; Kelsen D; O'Reilly EM J Gastrointest Cancer; 2011 Sep; 42(3):160-4. PubMed ID: 20711688 [TBL] [Abstract][Full Text] [Related]
15. A phase II study of intra-arterial chemotherapy of 5-fluorouracil, cisplatin, and mitomycin C for advanced nonresectable gastric cancer. Li M; Zhang J; Wang D; Zhong B; Tucker S; Lu C; Cheng J; Cao C; Xu J; Xu J; Pan H Anticancer Drugs; 2009 Nov; 20(10):941-5. PubMed ID: 19745719 [TBL] [Abstract][Full Text] [Related]
16. Does OPTIMOX strategy ("stop-and-go" approach) also work in treatment of pancreatic cancer with oxaliplatin-based regimens? Saif MW JOP; 2008 Sep; 9(5):658-63. PubMed ID: 18762700 [TBL] [Abstract][Full Text] [Related]
17. Perspectives in chemotherapy of pancreatic cancer. Klapdor R Eur J Surg Oncol; 1991 Apr; 17(2):153-66. PubMed ID: 1707835 [No Abstract] [Full Text] [Related]
18. BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts. Lohse I; Borgida A; Cao P; Cheung M; Pintilie M; Bianco T; Holter S; Ibrahimov E; Kumareswaran R; Bristow RG; Tsao MS; Gallinger S; Hedley DW Br J Cancer; 2015 Jul; 113(3):425-32. PubMed ID: 26180923 [TBL] [Abstract][Full Text] [Related]
19. Dramatic response of FOLFIRINOX regimen in a collision pancreatic adenocarcinoma patient with a germline BRCA2 mutation: a case report. Shimmura H; Kuramochi H; Jibiki N; Katagiri S; Nishino T; Araida T Jpn J Clin Oncol; 2019 Dec; 49(11):1049-1054. PubMed ID: 31612916 [TBL] [Abstract][Full Text] [Related]